BRCA2 and colorectal carcinoma: Taken together, this demonstrates that the BRCA2 knockdown increased the sensitivity of CRC cells towards olaparib, strongly supporting the notion that BRCA2 is a crucial influencing factor for the efficiency of olaparib treatment in CRC.